阿布昔替尼治疗黏膜类天疱疮的实时经验：病例报告
Real-Time Experience of Abrocitinib for the Treatment of Mucous Membrane Pemphigoid: A Case Report.
作者信息
Teng Yan, Ren Mingyang, Yang Xianhong, Lu Wei, Tao Xiaohua
机构信息
Center for Plastic & Reconstructive Surgery, Department of Dermatology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital of Hangzhou Medical College, Hangzhou, 310014, People's Republic of China.
出版信息
Patient Prefer Adherence. 2024 Feb 23;18:503-506. doi: 10.2147/PPA.S451007. eCollection 2024.
BACKGROUND
Mucous membrane pemphigoid (MMP), a rare autoimmune vesiculous and erosive disorder, may affect multiple mucous membranes, with the oral cavity being the most commonly affected site. Its treatment depends on the site(s) of mucosal involvement and disease severity.
PATIENTS AND METHODS
A 62-year-old female patient with MMP that predominantly involved the oral cavity strongly rejected systemic corticosteroid or immunosuppressive agents and was successfully treated with abrocitinib, a highly selective JAK-1 inhibitor with a good safety profile.
RESULTS
The case demonstrated good efficacy and safety profile of abrocitinib for the treatment of MMP with predominant oral involvement.
CONCLUSION
Abrocitinib is a promising agent for the treatment of MMP with oral involvement.
背景
黏膜类天疱疮（MMP）是一种罕见的自身免疫性水疱和糜烂性疾病，可累及多个黏膜，口腔是最常受累的部位。其治疗取决于黏膜受累部位和疾病严重程度。
患者和方法
一名62岁女性MMP患者，主要累及口腔，强烈拒绝全身使用糖皮质激素或免疫抑制剂，后成功接受了阿布昔替尼治疗，阿布昔替尼是一种安全性良好的高选择性JAK-1抑制剂。
结果
该病例显示阿布昔替尼治疗以口腔受累为主的MMP具有良好的疗效和安全性。
结论
阿布昔替尼是治疗口腔受累MMP的一种有前景的药物。
Zotero 插件